Enhancing liver cancer treatment with immune therapy and radiation
Official title: TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors
Funded at Roswell Park Cancer Institute Corp · NIH-11081783 · Data updated 2026-11-12
This study is exploring a new way to help cancer patients with liver tumors by using a combination of targeted radiation and a special immune therapy, hoping to boost the body's immune response and improve treatment outcomes for both liver and other tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | June 9, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $705,888 |
| NIH project number | 5R01CA278802-03 |
| Project ID | NIH-11081783 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with liver metastasis from various cancers who are undergoing or considering liver-directed radiotherapy and immune checkpoint blockade.
✕Less likely to help
Patients with primary liver cancers or those who do not have liver metastasis may not benefit from this research.
What this research studies
This research investigates a novel approach to treating liver metastasis in cancer patients by combining liver-directed radiotherapy with immune checkpoint blockade therapy. The study focuses on enhancing the immune response in the liver using a substance called entolimod, which activates specific immune pathways. By improving the effectiveness of these treatments, the goal is to achieve better control over both irradiated liver tumors and non-irradiated tumors elsewhere in the body. Patients may have the opportunity to participate in trials that assess the safety and efficacy of this combined treatment approach.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with liver metastasis by enhancing the effectiveness of existing therapies.
How similar studies have gone: Previous studies have shown promising results with similar immune-modulating therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Brackett, Craig M. — Roswell Park Cancer Institute Corp
- Study coordinator: Brackett, Craig M.
Related research
Other NIH-funded projects on the same topics.
-
TLR5-based boost for liver-directed radiotherapy plus immune therapy against liver metastases
A new treatment approach uses a TLR5-based signal to enhance liver-directed radiotherapy combined with immune checkpoint blockers to better control liver metastases and distant tumors.
-
Mapping HER2 and blood flow in HER2-positive breast cancer that has spread to the brain
Using advanced PET/MRI scans to map how HER2 protein and blood flow vary inside brain metastases in people with HER2-positive breast cancer before they get targeted drugs and radiation.
-
Using advanced imaging to understand HER2+ breast cancer spread to the brain
This study is looking at how HER2-positive breast cancer spreads to the brain and how well it responds to treatment, using special imaging techniques to help doctors find the best ways to target therapy for patients before they start radiation.
-
Lymph node metastasis and immune tolerance in head and neck cancer
A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A computer program helps plan radiation therapy for cervical and head-and-neck cancer patients to make treatments faster and more accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.